{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:28:57Z","timestamp":1765758537648,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jmii.2018.10.002","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T23:34:40Z","timestamp":1539300880000},"page":"556-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings"],"prefix":"10.1016","volume":"52","author":[{"given":"Cheng-Pin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huachun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Kuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2018.10.002_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jmii.2018.10.002_bib2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jmii.2018.10.002_bib3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/hep.25770","article-title":"Comparison of hepatitis C virus treatment between incarcerated and community patients","volume":"56","author":"Rice","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jmii.2018.10.002_bib4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2105\/AJPH.92.11.1789","article-title":"The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997","volume":"92","author":"Hammett","year":"2002","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jmii.2018.10.002_bib5","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.drugalcdep.2006.09.022","article-title":"Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users","volume":"91","author":"Campbell","year":"2007","journal-title":"Drug Alcohol Depend"},{"year":"2017","series-title":"New prisoners by type of offense in Ministry of Justice in Taiwan","key":"10.1016\/j.jmii.2018.10.002_bib6"},{"key":"10.1016\/j.jmii.2018.10.002_bib7","unstructured":"Taiwan National Infectious Diseases Statistics System of HIV\/AIDS in 2017. https:\/\/www.cdc.gov.tw\/english\/submenu.aspx?treeid=00ed75d6c887bb27&nowtreeid=f6f562fd95fd8df9."},{"key":"10.1016\/j.jmii.2018.10.002_bib8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1086\/587992","article-title":"Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV infected injection drug users in Taiwan","volume":"46","author":"Liu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2018.10.002_bib9","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.4254\/wjh.v7.i21.2323","article-title":"Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment","volume":"7","author":"Zampino","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jmii.2018.10.002_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/1471-2334-13-374","article-title":"HCV infected prisoners: should they be still considered a difficult to treat population?","volume":"13","author":"Iacomi","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2018.10.002_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1155\/2005\/767540","article-title":"Treatment of chronic hepatitis C in Canadian prison inmates","volume":"19","author":"Farley","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jmii.2018.10.002_bib12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1086\/591707","article-title":"Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations","volume":"47","author":"Maru","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2018.10.002_bib13","article-title":"Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection","volume":"13","author":"Cheng","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2018.10.002_bib14","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2018.10.002_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2018.10.002_bib16","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2018.10.002_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00535-018-1429-3","article-title":"The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection","volume":"53","author":"Zeuzem","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jmii.2018.10.002_bib18","doi-asserted-by":"crossref","first-page":"e6984","DOI":"10.1097\/MD.0000000000006984","article-title":"Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for na\u00efve hepatitis C patients with a real-world cohort and database","volume":"96","author":"Tsai","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jmii.2018.10.002_bib19","article-title":"Clinical features of acute human immunodeficiency virus infection in Taiwan: a multicenter study","author":"Lin","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2018.10.002_bib20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jmii.2016.11.004","article-title":"Viral dynamics of persistent hepatitis C virus infection in high-sensitive reporter cells resemble patient's viremia","volume":"51","author":"Tsai","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2018.10.002_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2018.10.002_bib22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3748\/wjg.v20.i11.2927","article-title":"Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication","volume":"20","author":"Thong","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jmii.2018.10.002_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmii.2015.01.006","article-title":"Molecular characterization of hepatitis C virus genotype 6 subtypes in Thai blood donors","volume":"50","author":"Sistayanarain","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2018.10.002_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.qai.0000214818.80539.da","article-title":"An epidemic of HIV type I CRF07_BC infection among injection drug users in Taiwan","volume":"42","author":"Lin","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2018.10.002_bib25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1086\/513437","article-title":"Molecular epidemiology of HIV-1 infection and full-length genomic analysis of circulating recombinant form 07_BC strains from injection drug users in Taiwan","volume":"195","author":"Lin","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2018.10.002_bib26","doi-asserted-by":"crossref","first-page":"e94791","DOI":"10.1371\/journal.pone.0094791","article-title":"Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection","volume":"9","author":"Hsieh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2018.10.002_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/apt.12551","article-title":"Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6","volume":"39","author":"Wantuck","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118218301233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118218301233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:24:46Z","timestamp":1761657886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118218301233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1684118218301233"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2018.10.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2018.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}